T- Cell Transfer as an Effective Cancer Immunotherapy: Systematic Review
|
|
- Egbert Osborne
- 5 years ago
- Views:
Transcription
1 T- Cell Transfer as an Effective Cancer Immunotherapy: Systematic Review 1 Sami Marei Ali Alqahtani, 2 Mohammed Awn Dhafer Alqahtani, 3 Jaber Ibrahim Jaber Assiri, 4 Albara Abdullah mohammad Al mushham, 5 Saleh Saeed Ali Alqarni, 6 Hatim Abdullah Hossain Ramza, 7 Khalid Hussain Mohammed Alhassani, 8 Assaf Abdullah Assaf Alkatheri Abstract: Significant effort has been extended over the past few years to evaluate the potential for adoptive T cell transfer to treat cancer. We aimed with this Systematic review study to evaluate the effectiveness of T cell transfer for cancer immunotherapy, also aimed to discuss the different approaches using this immunomodulation of T cell, and to overview those successful trails that have performed this method of treatment. Databases, PubMed, EMBASE, were searched to identified relevant trails discussing the effectiveness of T cell transfer for cancer immunotherapy; we searched for eligible studies that were published in English languages up to December Adoptive T cell transfer for cancer and chronic infection is an emerging field that shows promise in recent trials. Artificial biology-based engineering of T lymphocytes to reveal high affinity antigen-receptors can conquer immune tolerance, which has been a major restriction of immunotherapy-based techniques. Keywords: T cell transfer, Databases, PubMed, EMBASE. 1. INTRODUCTION Cancer is a leading cause of death worldwide, and the variety of cases worldwide continues to increase (1). Inning accordance with the World Cancer Report 2014, the global burden of cancer rose to an estimated 14 million brand-new cancer cases in 2012, and this figure is anticipated to rise to 22 million every year within the next twenty years. Over the exact same period, cancer deaths are predicted to increase from an estimated 8.2 million to 13 million each year. Many cancers can be prevented or cured if identified at an early stage and treated quickly. Due to the lack of perfect cancer biomarkers for early detection and medical diagnosis (2). The field of immunotherapy has experienced remarkable advancements over the past couple of years. To this end, the FDA approval of cell T for the treatment of hormonal agent refractory prostate cancer set the stage in 2010 (3), followed by the more current approvals of the PD-1 and CTLA-4 checkpoint repressive monoclonal antibodies (mab) in cancer malignancy and non-small cell lung cancer (NSCLC) (4). Significantly, many immunoregulatory mab focused on blocking repressive or boosting stimulatory immune signaling remain in development, some of which have currently been in medical testing alone or in combination with the currently approved obstructing antibodies with promising data, e.g., CD40 agonistic antibody in melanoma (5). Likewise, the use of adoptive cell transfer (ACT) utilizing in vitro expanded tumor penetrating lymphocytes (TIL) have actually revealed very strong clinical efficacy in stage II trials (6,7), and the administration of T cells harnessed with tumor specific T-cell receptors, show excellent guarantee likewise beyond solid cancer, e.g., myeloma (8). The excellent majority up to-date targeted tumor antigens are self-antigens, typically expressed during advancement and aberrantly expressed by tumors. The striking distinction in affinity between T cell receptors specific for self-antigens expressed by tumors and T cell receptors particular for infection antigens has been summed up just recently (9). Comparative analyses have exposed that TCR from T cells that recognize self-tumor antigens have significantly lower affinities (approximately 0.5 logs) for cognate MHC: peptide complexes compared to their virusspecific equivalents (10). This observation, which shows the impact of main tolerance on the T cell collection to selfantigens, indicate the fact that T cells that get away central tolerance and have the prospective to respond to the self-target Page 699
2 antigens will manifest for the most parts suboptimal activation in regards to antitumor activity (10). The high tolerance to tumor antigens with developmental and/or regular expression combined with the potent immunosuppressive microenvironment often present at the tumor site support the premise that improving anti-tumor immunity by the adoptive transfer of "native" T cells might not be sufficient to induce tumor cell death in most patients with advanced malignancy (10).Gene-transfer based methods have been established to get rid of the consequences of immune tolerance on the tumorspecific T cell repertoire. These approaches provide the potential to reroute T cells to efficiently target tumors by the transfer of antigen-specific T cell receptor α and β chains (αβ TCR) or chimeric antigen receptors (CAR) made up of antibody binding domains fused to T cell signaling domains. In each case recipient T cells get the crafted, tumor-specific uniqueness while keeping their initial uniqueness (Figure1) (11). Figure 1: Engineered T cells that have retargeted specificity (11) We aimed with this Systematic review study to evaluate the effectiveness of T cell transfer for cancer immunotherapy, also aimed to discuss the different approaches using this immunomodulation of T cell, and to overview those successful trails that have performed this method of treatment. 2. METHODS Our study was conducted according PRISMA guideline for systematic reviews. Search methods: Databases, PubMed, EMBASE, were searched to identified relevant trails discussing the effectiveness of T cell transfer for cancer immunotherapy, we searched for eligible studies that were published in English languages up to December 2016, we did not limit our search for only human subject trails, we also included animal models and trails that were performed in vivo. in this search strategy we use couple of Mesh terms to find more appropriate articles to be included in our review and these terms were as following; T cell transfer, adaptive cell transfer AND immunotherapy, cancer, tumor, treatment. All terms were combined in several steps, we also searched references of included studies for more relevant articles to our topic. General aspects: 3. RESULTS & DISCUSSION The inherent and obtained immune systems play a vital function in immune security and immune defense (12,13). For that reason, the use of the body immune system to remove cancer is a very appealing technique for cancer treatment (14,15). Indeed, immunotherapy has actually demonstrated great prospective for cancer treatment (16,17,18,19), particularly for disease refractory to standard treatments, consisting of chemotherapy, surgery and radiotherapy. Cancer immunotherapy approaches consist of active immunization, nonspecific immune stimulation and ACT. Among these techniques, ACT has accomplished more exciting lead to cancer medical trials and therefore, holds the most promise for the treatment of malignant diseases (20,21,22,23). Cancer immunotherapy needs the activation and growth of cancer-specific T cells, which kill cancer cells by recognizing antigen targets expressed on cancer cells. Over the past 20 years, research studies have actually revealed that the generation of cancer-specific resistance needs 3 actions (Figure 2) (34). First, antigen-presenting cells (e.g., dendritic cells [ DCs] capture and procedure cancer antigens into antigenic peptides, which exist in combination with human leukocyte Page 700
3 antigen (HLA) particles for recognition by TCR of T cells (signal 1) (25). Second, T-cell activation requires the binding of the costimulatory surface molecules B7 and CD28 on antigen-presenting cells and T cells, respectively (signal 2). To accomplish ideal T-cell activation, both signals 1 and 2 are needed. On the other hand, antigenic peptide stimulation (signal 1) in the absence of costimulation (signal 2) cannot cause complete T-cell activation, therefore leading to T-cell tolerance. In addition to costimulatory particles, there are also repressive particles, such as CTLA-4 and PD-1, which induce signals to prevent T-cell activation (26). Third, activated cancer-specific T cells reach tumor sites and acknowledge tumor antigens revealed by cancer cells, therefore killing the cancer cells. Antigenic peptide stimulation initiates T-cell activation, the degree of T-cell activation is more identified by the balance between costimulation and cosuppression. Recent scientific trials have actually shown that blockade of PD-1 coinhibition with anti-pd-l1 or anti-pd-1 therapy boosts T-cell-mediated anticancer responses without severe unfavorable occasions (SAE) (27,28). Inhibition of CTLA-4 signaling has been revealed to significantly enhance the survival of patients with late-stage cancer malignancy (29,30), leading to the FDA approval of the anti-ctla-4 antibody ipilimumab (Yervoy) for metastatic melanoma in Besides T-cellintrinsic regulation, T-cell activation can likewise be controlled by external factors (extrinsic). For example, cytokines, such as IL-2, released by CD4+ assistant T cells (Th1 and Th17) can straight promote cancer-specific T cell expansion, while IL-2 might likewise moderate growth of CD4+ Treg, which antagonize function of cancer-specific T cells (31). On the other hand, myeloid-derived suppressor cells (MDSCs) and T cells, which are normally present in the tumor microenvironment, prevent cancer-specific T cell function and induce immunosuppression (32,33), causing bad immunotherapy efficacy. Figure 2: The key points in cancer immunotherapy are one activation and two inhibitions where cancer-reactive T-cell activation by cancer antigen represents the one activation and blockade of coinhibitory molecules on T cells and reversal of Treg cell-mediated immunosuppression represent the two inhibitions. DC: Dendritic cell. (34) Roles of T cell in Immunotherapy: Effective T cell-based active immunotherapy requires not only the expression of antigens by cancer cells however likewise the successful and sustained mobilization of sufficient varieties of effector T cells that recognize these antigens in order to remove the tumour. T cell activation is started by stimulation of the antigen receptor (T cell receptor (TCR)) with significant histocompatibility complex (MHC) particles, which present peptides that are derived from tumour antigens. For efficient activation, this must be accompanied by co-stimulatory signals mediated by the binding of CD28 on the T cell surface to B7 proteins (such as CD80 or CD86) on the antigen-presenting cell (APC). This is mediated by the administration of the T-cell development factor interleukin 2 (IL2) and can activate endogenous tumour-reactive cells in vivo and reproducibly trigger the regression of some human strong cancers (35,36,37) The resilience of the cancer regressions induced by IL2 resulted in its approval by the US Food and Drug Administration for the treatment of patients with metastatic kidney cancer in 1992 and metastatic cancer malignancy in IL2 administration leads to toxicity owing to a capillary leakage syndrome, experience with the administration of this cytokine has resulted in treatmentrelated mortalities of <1% (38). More just recently, antibody-mediated blockade of a cell surface area repressive molecule, cytotoxic T-lymphocyte-associated 4 (CTLA4), has resulted in objective clinical reactions in % of patients, but once again just consistently in those with metastatic melanoma or renal cancer, recommending that these 2 tumour types are remarkable in their ability to naturally create endogenous anti-tumour cells of adequate avidity and in sufficient numbers to moderate cancer regression when properly promoted in vivo (39,40). Page 701
4 Sipuleucel-T (Provenge) and ipilimumab (Yervoy) have actually been authorized by the FDA for treatment of prostate cancer and metastatic melanoma, respectively (7,8), and a Phase III scientific trial of the gp100 peptide-based vaccine in patients with cancer malignancy likewise produced encouraging results (11). Nevertheless, the medical advantages reported for these representatives have actually fallen far except complete reactions and long-term treatments, although the scientific data for ipilimumab are still emerging. On the other hand, ACT therapy using cancer antigen-specific T cells including TILs, peptide-induced T cells and engineered T cells (TCR and CAR) has actually shown significant strength in cancer treatment (20,21), leading to complete and long lasting actions in some patients with late-stage and refractory disease. Here, we will present a summary of the most amazing clinical outcomes gotten with ACT summarized in (Table 1) and also discuss future instructions of ACT-based cancer immunotherapy. Table 1: Identified clinical trials using T-cell-based immunotherapy. Malignancy Patient number Type of T cells infused Target antigen Clinical outcomes Metastatic melanoma 20 TIL Unknown 1 CR, 10 PR, 1 MR Metastatic melanoma 13 TIL Unknown 6 PR, 4 MR Metastatic melanoma 93 TIL Unknown 22 CR, 34 PR Metastatic melanoma 10 CD8 + T cells MART1/MelanA or gp SD, 1 MR, 2 minor response Metastatic melanoma 11 CD8 + T cells MelanA 1 CR, 1 PR, 1 MR, 1 SD Metastatic melanoma 1 CD4 + T cells NY-ESO-1 1 CR Metastatic melanoma 14 CD8 + T cells MelanA 2 CR, 4 PR, 1 SD Metastatic melanoma 11 CD8 + T cells MART1/Tyr/gp CR, 5 SD Metastatic melanoma 17 TCR T cells MART1 2 PR, 1 MR Metastatic melanoma 36 High affinity TCR T cells MART1 or gp CR, 8 PR Metastatic melanoma 3 TCR T cells CEA 1 PR Metastatic melanoma/ synovial sarcoma 17 TCR T cells NY-ESO-1 2 CR, 7 PR Metastatic melanoma 9 High affinity TCR T cells MAGEA3/MAGEA12 1 CR, 4 PR Metastatic melanoma/ myeloma 2 High affinity TCR T cells MAGEA3/Titin Not evaluable Neuroblastoma 19 CAR T cells GD2 3 CR Renal carcinoma 12 CAR T cells CAIX Not evaluable Colon cancer 1 CAR T cells (CD28-4-1BB- CD3ζ) ERBB2 Lymphoma 1 CAR T cells (CD28-CD3ζ) CD19 1 PR Not evaluable Lymphoma and CLL 8 CAR T cells (CD28-CD3ζ) CD19 1 CR, 5 PR, 1 SD CLL 3 CAR T cells (4-1BB-CD3ζ) CD19 2 CR, 1 PR ALL 2 CAR T cells (4-1BB-CD3ζ) CD19 2 CR ALL 5 CAR T cells (CD28-CD3ζ) CD19 5 CR ALL 16 CAR T cells (CD28-CD3ζ) CD19 14 CR Ref. (41) (42) (7) (43) (44) (45) (46) (47) (48) (49) (50) (51) (52) (53,54) (55) (56) (57) (58) (59) (60,61) (62) (63) (64) ALL: Acute lymphoblastic leukemia; CAR: Chimeric antigen receptor; CEA: Carcinoembryonic antigen; CLL: Chronic lymphocytic leukemia; CR: Complete response; MR: Mixed response; PR: Partial response; SD: Stable disease; TCR: T- cell receptor; TIL: Tumor-infiltrating lymphocyte. Page 702
5 4. CONCLUSION Adoptive T cell transfer for cancer and chronic infection is an emerging field that shows promise in recent trials. Artificial biology-based engineering of T lymphocytes to reveal high affinity antigen-receptors can conquer immune tolerance, which has been a major restriction of immunotherapy-based techniques. Advances in cell engineering and culture techniques to make it possible for efficient gene transfer and ex vivo cell growth have actually helped with broader examination of this technology, moving adoptive transfer from a "shop" application to the cusp of a mainstream technology. The major obstacle currently facing the field is to increase the uniqueness of engineered T cells for tumors, since targeting shared antigens has the potential to cause on-target off-tumor toxicities, as observed in current trials. Recently deficiency of T reg cells has actually been revealed to enhance reactivity to tumor/self-antigens in tumor avoidance models, but we reveal for the very first time that T reg cells can hinder aid of self-reactive CD4+ T cells and avoid effector CD8+ T cells from initiating autoimmunity. T reg cells control peripheral self-tolerance through yet unknown systems, but our company believe that gradually growing tumors shed or secrete self-antigens that consequently trigger naturally taking place T reg cells. REFERENCES [1] Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2): [2] Wagner PD, Srivastava S. New paradigms in translational science research in cancer biomarkers. Transl Res. 2012;159(4): [3] nyder A, Tepper JE, Slovin SF. Perspectives on immunotherapy in prostate cancer and solid tumors: where is the future? Semin Oncol. 2013;40: [4] First Immunotherapy Combo Approved for Cancer: Cancer Discov 2015;5: [5] Honeychurch J, Cheadle EJ, Dovedi SJ, Illidge TM. Immuno-regulatory antibodies for the treatment of cancer. Expert Opin Biol Ther. 2015;15: [6] Andersen R, Donia M, Ellebaek E, Holz Borch T, Kongsted P, Iversen TZ, Rosenkrantz Hölmich L, Westergren Hendel H, Met O, Hald AM, thor Straten P, Svane IM. Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin Cancer Res Epub ahead of print. [7] Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17: [8] Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. NY-ESO-1-specific TCRengineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015;21: [9] Aleksic M, Liddy N, Molloy PE, Pumphrey N, Vuidepot A, Chang KM, Jakobsen BK. Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies. Eur J Immunol. 2012;42: [10] Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK. Human TCR-binding affinity is governed by MHC class restriction. Journal of immunology. 2007;178: [11] Kalos M, June CH. Adoptive T cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology. Immunity. 2013;39(1): /j.immuni doi: /j.immuni [12] Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29: Page 703
6 [13] Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity s roles in cancer suppression and promotion. Science. 2011;331(6024): [14] Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer what clinicians need to know. Nat Rev Clin Oncol. 2011;8(10): [15] Wang HY, Wang RF. Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling. Adv Immunol. 2012;114: [16] Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-cd19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5): [17] Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. 2012;12(4): [18] Sharma P, Wagner K, Wolchok JD, Allison JP. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat Rev Cancer. 2011;11(11): [19] Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378): [20] Ruella M, Kalos M. Adoptive immunotherapy for cancer. Immunol Rev. 2014;257(1): [21] Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev. 2014;257(1): [22] Hinrichs CS, Rosenberg SA. Exploiting the curative potential of adoptive T-cell therapy for cancer. Immunol Rev. 2014;257(1): Overview of adoptive T-cell-based immunotherapy. [23] Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. 2014;257(1): [24] Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev. 2014;257(1): [25] Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12(4): [26] Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4): [27] Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-pd-1 antibody in cancer. N Engl J Med. 2012;366(26): [28] Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-pd-l1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26): [29] Hodi FS, O Day SJ, Mcdermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8): [30] Royal RE, Levy C, Turner K, et al. Phase 2 trial of single agent Ipilimumab (anti-ctla-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33(8): [31] Shevach EM. Application of IL-2 therapy to target T regulatory cell function. Trends Immunol. 2012;33(12): [32] Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol. 2007;19(2): [33] Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7): [34] Wang M, Yin B, Wang HY, Wang R-F. Current advances in T-cell-based cancer immunotherapy. Immunotherapy. 2014;6(12): doi: /imt [35] Rosenberg SA, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985;313: Page 704
7 [36] Rosenberg SA, Yang JC, White DE, Steinberg SM. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2. Ann. Surg. 1998;228: [37] Lotze MT, et al. High dose recombinant interleukin-2 in the treatment of patients with disseminated cancer: responses, treatment related morbidity and histologic findings. J. Am. Med. Assoc. 1986;256: [38] Kammula US, White DE, Rosenberg SA. Trends in the safety high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83: [39] Phan GQ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA. 2003;100: [40] Attia P, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anticytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 2005;23: [41] Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25): The first tumor-infiltrating lymphocyte based clinical trial in melanoma patients [42] Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594): [43] Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA. 2002;99(25): [44] Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol. 2006;24(31): [45] Hunder NN, Wallen H, Cao J, et al. Treatment of metastatic melanoma with autologous CD4+ T cells against. NY- ESO-1. N Engl J Med. 2008;358(25): [46] Khammari A, Labarriere N, Vignard V, et al. Treatment of metastatic melanoma with autologous Melan-A/MART- 1-specific cytotoxic T lymphocyte clones. J Invest Dermatol. 2009;129(12): [47] Chapuis AG, Thompson JA, Margolin KA, et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci USA. 2012;109(12): [48] Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796): The first report of an antigen-specific T-cell receptor-transduced T-cell-based clinical trial in patients. [49] Johnson LA, Morgan RA, Dudley ME, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009;114(3): [50] Parkhurst MR, Yang JC, Langan RC, et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011;19(3): [51] Robbins PF, Morgan RA, Feldman SA, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29(7): [52] Morgan RA, Chinnasamy N, Abate-Daga D, et al. Cancer regression and neurological toxicity following anti- MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2): [53] Cameron BJ, Gerry AB, Dukes J, et al. Identification of a Titin-derived HLA-A1-presented peptide as a crossreactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra103. [54] Linette GP, Stadtmauer EA, Maus MV, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6): [55] Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23): Page 705
8 [56] Lamers CH, Sleijfer S, Van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CARengineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013;21(4): [57] Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4): [58] Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20): [59] Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-cd19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12): [60] Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8): Chimeric antigen receptor (CAR)-transduced T-cell-based clinical trial showing great success in treatment of chronic lymphoid leukemia. [61] Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73. [62] Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16): CAR-transduced T-cell-based clinical trial showing great success in treatment of acute lymphoid leukemia. [63] Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra138. CAR-transduced T- cell-based clinical trial showing great success in treatment of acute lymphoblastic leukemia. [64] Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19 28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225. Page 706
Tumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationImmunotherapy on the Horizon: Adoptive Cell Therapy
Immunotherapy on the Horizon: Adoptive Cell Therapy Joseph I. Clark, MD, FACP Professor of Medicine Loyola University Chicago Stritch School of Medicine Maywood, IL June 23, 2016 Conflicts of Interest
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationDeveloping Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationAdoptive Cell Therapy: Treating Cancer
Adoptive Cell Therapy: Treating Cancer with Genetically Engineered T Cells Steven A. Feldman, Ph.D. Surgery Branch National Cancer Institute NCT Conference Heidelberg, Germany September 24, 2013 Three
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationAdoptive Cellular Therapy SITC Primer October 2012
Adoptive Cellular Therapy SITC Primer October 2012 Cassian Yee MD Member Fred Hutchinson Cancer Research Center Program in Immunology Clinical Research Division Professor University of Washington Division
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationHHS Public Access Author manuscript J Clin Cell Immunol. Author manuscript; available in PMC 2017 April 01.
Genetically Modified T-cell Therapy for the Treatment of Osteosarcoma: An Update Christopher DeRenzo 1,2,3 and Stephen Gottschalk 1,2,3,4,* 1 Center for Cell and Gene Therapy, Texas Children s Hospital,
More informationInterleukin-2 Single Agent and Combinations
Interleukin-2 Single Agent and Combinations Michael K Wong MD PhD Norris Cancer Center University of Southern California mike.wong@med.usc.edu Disclosures Advisory Board Attendance Merck Bristol Myers
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationImmunotherapy Concept Turned Reality
Authored by: Jennifer Dolan Fox, PhD VirtualScopics Inc. jennifer_fox@virtualscopics.com +1 585 249 6231 Immunotherapy Concept Turned Reality Introduction While using the body s own immune system as a
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationTumor Antigens in the Age of Engineered T cell Therapies
Tumor Antigens in the Age of Engineered T cell Therapies September 30 th 2016 ESMO Preceptorship Course Amsterdam Carsten Linnemann, PhD Senior Scientist Kite Pharma EU B.V. Amsterdam Forward Looking Statements/Safe
More informationImmunocore Ltd isbtc Washington 30 th October 2009
Ltd isbtc Washington 30 th October 2009 Bent Jakobsen Chief Scientific Officer Breaking immune tolerance to cancer The immune system has more cytotoxic potential and versatility than can be achieved with
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationGSK Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. March 8, 2017
GSK Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D March 8, 217 GSK pipeline Oncology R&D Strategy Maximizing survival through transformational medicines and combinations Cancer Epigenetics
More informationGENETICALLY ENHANCED CANCER THERAPIES
GENETICALLY ENHANCED CANCER THERAPIES Hello! I am Tapani Ronni Science talks to translators and interpreters since 2012. You can find me at: www.polarbearcommunications.com ATA 2018 2 About the speaker
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationCheckpoint Regulators Cancer Immunotherapy takes centre stage. Dr Oliver Klein Department of Medical Oncology 02 May 2015
Checkpoint Regulators Cancer Immunotherapy takes centre stage Dr Oliver Klein Department of Medical Oncology 02 May 2015 Adjuvant chemotherapy improves outcome in early breast cancer FDA approval of Imatinib
More informationTumor Immunology: A Primer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationNIH Public Access Author Manuscript Science. Author manuscript; available in PMC 2008 March 12.
NIH Public Access Author Manuscript Published in final edited form as: Science. 2006 October 6; 314(5796): 126 129. Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes Richard
More informationDarwinian selection and Newtonian physics wrapped up in systems biology
Darwinian selection and Newtonian physics wrapped up in systems biology Concept published in 1957* by Macfarland Burnet (1960 Nobel Laureate for the theory of induced immune tolerance, leading to solid
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationCloning and expansion of antigen-specific T cells using ipsc technology: A novel strategy for cancer immunotherapy
Inflammation and Regeneration Vol.35 No.5 November 2015 220 Special Issue: Immunoregulation in regenerative medicine Mini Review Cloning and expansion of antigen-specific T cells using ipsc technology:
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationCANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients
CANCER MEDICINES IN DEVELOPMENT 2018 REPORT JUST THE FACTS MORE THAN 1.7 M ESTIMATED NEW CASES OF CANCER IN 2018 IN THE UNITED STATES MORE THAN 609,000 U.S. CANCER DEATHS ARE EXPECTED IN 2018 SINCE PEAKING
More informationThe Role of Immunotherapy in Prostate Cancer: What s Trending?
The Role of Immunotherapy in Prostate Cancer: What s Trending? Douglas G. McNeel, MD, PhD University of Wisconsin Carbone Cancer Center Madison, Wisconsin Prostate cancer rationale for immune therapies
More information9/22/2016. Introduction / Goals. What is Cancer? Pharmacologic Strategies to Treat Cancer. Immune System Modulation
Immunomodulatory Therapies in Cancer Treatment Bill O Hara, PharmD, BCPS, BCOP Advanced Practice Pharmacist, Oncology/BMT Thomas Jefferson University Hospital Introduction / Goals What is Cancer? How can
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationAdvances in Adoptive Cellular Therapy of Cancer. Melanoma Bridge Meeting December 5, 2014
Advances in Adoptive Cellular Therapy of Cancer Melanoma Bridge Meeting December 5, 2014 David Stroncek, MD Chief, Cell Processing Section, DTM, CC, NIH Bethesda, Maryland, USA Disclosures None Focus
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationChildren s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant
Children s Hospital of Philadelphia Annual Progress Report: 2011 Formula Grant Reporting Period January 1, 2012 June 30, 2012 Formula Grant Overview The Children s Hospital of Philadelphia received $3,521,179
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy
ACTR (Antibody Coupled T-cell Receptor): A universal approach to T-cell therapy European Medicines Agency Workshop on Scientific and Regulatory Challenges of Genetically Modified Cell-based Cancer Immunotherapy
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationHistorical overview of immunotherapy
Historical overview of immunotherapy Before introduction of immune checkpoint inhibitors John B.A.G. Haanen, MD PhD My Disclosures I have provided consultation, attended advisory boards, and/or provided
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More informationOverview 4/11/2013. Cell Kinetics in Adoptive Cell Therapy. April 11, 2013
Cell Kinetics in Adoptive Cell Therapy April 11, 2013 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationIs Immune Therapy the Holy Grail in Metastatic Kidney Cancer?
Is Immune Therapy the Holy Grail in Metastatic Kidney Cancer? New Frontiers in Urologic Oncology 8-2016 Mayer Fishman, MD PhD Member, Moffitt Cancer Center Department of Genitourinary Oncology Professor,
More informationCombining ADCs with Immuno-Oncology Agents
Combining ADCs with Immuno-Oncology Agents Chad May, PhD Senior Director Targeted Immunotherapy Oncology Research Unit, Pfizer 7 th Annual World ADC October 10, 2016 Cancer-Immunity Cycle Innate Immunity
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationImmuno-Oncology. Axel Hoos, MD, PhD Senior Vice President, Oncology R&D. February 24, 2016
Immuno-Oncology Axel Hoos, MD, PhD Senior Vice President, Oncology R&D February 24, 216 GSK Pipeline Oncology R&D strategy Focusing on 3 areas fundamental to oncology Cancer Epigenetics Long-Term Survival
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationImmuno-Oncology Applications
Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationUnderstanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.
Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research
More informationAbstract #163 Michael Kalos, PhD
LONG TERM FUNCTIONAL PERSISTENCE, B CELL APLASIA AND ANTI LEUKEMIA EFFICACY IN REFRACTORY B CELL MALIGNANCIES FOLLOWING T CELL IMMUNOTHERAPY USING CAR REDIRECTED REDIRECTED T CELLS TARGETING CD19 Abstract
More informationBihong Zhao, M.D, Ph.D Department of Pathology
Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationI farmaci immunoterapici. Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa
I farmaci immunoterapici Stefano Fogli UO Farmacologia Clinica e Farmacogenetica Dipartimento di Medicina Clinica e Sperimentale Università di Pisa History of Cancer Immunotherapy Discovery of dendritic
More informationCBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology
CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationDisclosure Information. Mary L. Disis
Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:
More informationCANCER IMMUNOTHERAPY. Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL
FARMAFORUM 2015 FACULTAD FARMACIA CANCER IMMUNOTHERAPY Cancer Research Center, Dpt. of Medicine & Service of Cytometry University of Salamanca. IBSAL The immune response to tumors Oncogenic event The immune
More informationBASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION
BASIC MECHANISM OF TUMOR IMMUNE SUPPRESSION Zihai Li, M.D., Ph.D. Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC) DISCLOSURE GOALS Understand that immune
More informationTITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer
AD Award Number: W8-XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke, Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationLecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells
1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationAdverse effects of Immunotherapy. Asha Nayak M.D
Adverse effects of Immunotherapy Asha Nayak M.D None Financial Disclosures Objectives Understand intensity of the AEs. Understanding unique side-effects. Develop effective monitoring and management guidelines.
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationThe Emerging Role of Immunotherapy in Cancer Care Renato V. La Rocca, MD, FACP Norton Cancer Institute Louisville, Kentucky
The Emerging Role of Immunotherapy in Cancer Care 2015 Renato V. La Rocca, MD, FACP Norton Cancer Institute Louisville, Kentucky Renato V. La Rocca, MD, FACP I have no conflicts to disclose with respect
More informationVISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
More information5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
More informationRXi Pharmaceuticals. Immuno-Oncology World Frontiers Conference. January 23, 2018 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals Immuno-Oncology World Frontiers Conference January 23, 2018 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationCancer Immunotherapy. What is it? Immunotherapy Can Work! 4/15/09. Can the immune system be harnessed to fight cancer? T CD4 T CD28.
Cancer Immunotherapy CANCER BIOLOGY April 15, 2009 Can the immune system be harnessed to fight cancer? Can the immune system see cancer? What is the best way to turn on the immune system to fight cancer?
More informationInnovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014 Bernd Mueller MSD Sharp & Dohme, Germany Normal Immune Surveillance:
More informationCancer Progress. The State of Play in Immuno-Oncology
Cancer Progress The State of Play in Immuno-Oncology Axel Hoos, MD, PhD VP, Oncology R&D, Glaxo Smith Kline Co-Director, Cancer Immunotherapy Consortium Key Drivers in Immuno-Oncology Science Methods Combinations
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationCAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER. Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th Paris
CAR T-CELLS: ENGINEERING IMMUNE CELLS TO TREAT CANCER Roman GALETTO, PhD 17 th Club Phase 1 Annual Meeting April 5 th 2018 - Paris Cellectis, 05-APR-2018 2 FORWARD-LOOKING STATEMENTS THIS PRESENTATION
More informationReview Article Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
Hindawi Journal of Immunology Research Volume 2017, Article ID 5210459, 13 pages https://doi.org/10.1155/2017/5210459 Review Article Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological
More informationThe Immunotherapy of Oncology
The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant
More informationOverview 3/31/2016. Cell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red Cells
More informationCell Kinetics in Adoptive Cell Therapy. March 31, 2016
Cell Kinetics in Adoptive Cell Therapy March 31, 2016 David Stroncek, MD Chief, Cellular Processing Section DTM, CC, NIH 1 Cellular Therapies Cell suspensions used for therapeutic purposes Examples Red
More informationEvaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors
Evaluation of an Agonist Anti-CD27 Human Antibody (Varlilumab) and its Potential for Combination With Checkpoint Inhibitors Tibor Keler, PhD Chief Scientific Officer Enhancing immunity with immune modulating
More informationTrial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor
Supplemental table 1. Overview of recent clinical phase I and II trials assessing the safety and efficacy of TCR-modified T cells in cancer patients as registered at clinicaltrials.gov by September 1,
More informationExploring the PD-L1 Pathway
Active Within the tumor microenvironment Steps 1-3: Initiating and propagating anticancer immunity 1 may inhibit T-cell activity in the tumor microenvironment Dendritic cells capture cancer and then prime
More informationDaratumumab: Uncovering a novel mechanism of action for an approved antibody therapy
Daratumumab: Uncovering a novel mechanism of action for an approved antibody therapy Dr. Kate Sasser, PhD Corporate VP, Translational Research December 14 th, 2017 CD38 is ubiquitously expressed in Myeloma
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationImmunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells
Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More information